Jinying Lu

Abstract Patients with impaired tumour-specific major histocompatibility complex class I (tsMHC-Iimpaired) often fail to respond to immune checkpoint blockade (ICB), presenting a major clinical challenge. However, through our multicentre investigation, we observed that a subset of patients with tsMHC-Iimpaired remains responsive to ICB, a phenomenon that has not been fully explained. Here we identify a COTL1high natural killer (NK) subset that mediates ICB responsiveness in these patients.

Conflicts of Interest The authors declare no conflicts of interest. Data Availability Statement The data and analytical code necessary to reproduce the analyses presented in this paper are available by contacting the corresponding author(s). The materials necessary to attempt to replicate the findings presented in this paper are available by contacting the corresponding author(s). The analyses presented here were not preregistered.